Saltar al contenido
Merck

The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.

Bioorganic & medicinal chemistry letters (2008-04-29)
Hirofumi Omura, Makoto Kawai, Akiko Shima, Yasuhiro Iwata, Fumitaka Ito, Tsutomu Masuda, Atsuko Ohta, Naoya Makita, Kiyoyuki Omoto, Hiromi Sugimoto, Akira Kikuchi, Hiroshi Iwata, Kazuo Ando
RESUMEN

Benzimidazolone derivatives were discovered as novel CB2 selective agonists. Structure Activity Relationship (SAR) studies around them were examined to improve metabolic stability. Compound 39 exhibited excellent metabolic stability in human liver microsomes (HLM) and significant attenuation of the chronic colonic allodynia in the TNBS-treated rats by po administration.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
4-(2-Keto-1-benzimidazolinyl)piperidine, 98%